Medindia

X

User Base for Novartis' Cosentyx in Psoriatic Arthritis Significantly Expands as Rheumatologists Report High Satisfaction

Friday, August 12, 2016 General News J E 4
Advertisement
At nearly six months post launch, three-quarters of US rheumatologists report having prescribed Cosentyx, a significant increase from the 24% who reported use at one month post-launch, according to a recent report from Spherix Global Insights.

CAMBRIDGE, Mass., Aug. 11, 2016 /PRNewswire/ -- US rheumatologists are increasingly adopting Novartis' IL-17 inhibitor, Cosentyx, into their treatment algorithm for psoriatic arthritis (PsA). Cosentyx users report high levels of satisfaction and excitement about the results their PsA patients are achieving with the latest biologic, with over one-quarter of current users citing that they are extremely satisfied with the agent.  Furthermore, half of current non-users anticipate initiating trial of Cosentyx within the next three months.

With Cosentyx prescriptions in PsA on the rise, over one-third of rheumatologists believe that Janssen's Stelara is the most likely to be replaced.  Additionally, one-third of rheumatologists also report that Cosentyx has a significant efficacy advantage over Stelara.

With respect to Celgene's Otezla, rheumatologists believe Cosentyx has a significant advantage over Otezla regarding efficacy in PsA. Indeed, rheumatologists report lower overall satisfaction with the PDE4 inhibitor than with the biologics available in PsA.

Cosentyx appears to be paving the PsA highway for IL-17 inhibitors, much like it paved the way for early adoption of Eli Lilly's Taltz (ixekizumab) in Psoriasis.  Indeed, the vast majority of surveyed rheumatologists foresee a role for Taltz, as well as for Valeant and AstraZeneca's Siliq (brodalumab) in the future treatment of PsA. Furthermore, the majority of rheumatologists agree that the addition of IL-17 inhibitors as treatment options will greatly improve their ability to efficiently treat PsA.

RealTime Dynamix™: Psoriatic Arthritis, is an independent report issued on a quarterly basis that provides highly granular brand insights on the PsA market.  The Q2 report highlighted here provides insight from 100 US rheumatologists.

About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and market research company. We specialize in renal, autoimmune, neurologic and rare disease markets.  Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.

For more information contact: Lynn Price, Immunology Franchise HeadEmail: lynn.price@spherixglobalinsights.com www.spherixglobalinsights.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/user-base-for-novartis-cosentyx-in-psoriatic-arthritis-significantly-expands-as-rheumatologists-report-high-satisfaction-300312644.html

SOURCE Spherix Global Insights

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Gateway Health to Sponsor Citicamp's Fantastic Fin...
S
HealthSTAR Communications Hires Industry Veteran J...